| Literature DB >> 35736639 |
Yukino Kato1, Kenji Tago2, Shoya Fukatsu1, Miyu Okabe1, Remina Shirai1, Hiroaki Oizumi3, Katsuya Ohbuchi3, Masahiro Yamamoto3, Kazushige Mizoguchi3, Yuki Miyamoto1,4, Junji Yamauchi1,4.
Abstract
Angiotensin-converting enzyme 2 (ACE2) plays a role in catalyzing angiotensin II conversion to angiotensin (1-7), which often counteracts the renin-angiotensin system. ACE2 is expressed not only in the cells of peripheral tissues such as the heart and kidney, but also in those of the central nervous system (CNS). Additionally, ACE2 acts as the receptor required for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), whose binding leads to endocytotic recycling and possible degradation of the ACE2 proteins themselves. One of the target cells for SARS-CoV-2 in the CNS is oligodendrocytes (oligodendroglial cells), which wrap neuronal axons with their differentiated plasma membranes called myelin membranes. Here, for the first time, we describe the role of ACE2 in FBD-102b cells, which are used as the differentiation models of oligodendroglial cells. Unexpectedly, RNA knockdown of ACE2 with CasRx-mediated gRNA or the cognate siRNA promoted oligodendroglial cell morphological differentiation with increased expression or phosphorylation levels of differentiation and/or myelin marker proteins, suggesting the negative role of ACE2 in morphological differentiation. Notably, ACE2's intracellular region preferentially interacted with the active GTP-bound form of Ras. Thus, knockdown of ACE2 relatively increased GTP-bound Ras in an affinity-precipitation assay. Indeed, inhibition of Ras resulted in decreasing both morphological differentiation and expression or phosphorylation levels of marker proteins, confirming the positive role of Ras in differentiation. These results indicate the role of ACE2 itself as a negative regulator of oligodendroglial cell morphological differentiation, newly adding ACE2 to the list of regulators of oligodendroglial morphogenesis as well as of Ras-binding proteins. These findings might help us to understand why SARS-CoV-2 causes pathological effects in the CNS.Entities:
Keywords: ACE2; Ras; differentiation; oligodendrocyte; oligodendroglial cell
Year: 2022 PMID: 35736639 PMCID: PMC9229887 DOI: 10.3390/ncrna8030042
Source DB: PubMed Journal: Noncoding RNA ISSN: 2311-553X
Key antibodies and chemical sources. All key materials such as antibodies are shown.
| Reagent or Source | Company or Source | Cat. No. | Lot. No. | Concentration Used |
|---|---|---|---|---|
| Antibodies | ||||
| Anti-proteolipid protein (PLP) 1 | Atlas Antibodies | HPA004128 | B115828 | IB, 1/500 |
| Anti-cyclic nucleotide 3′-phosphodiesterase (CNPase) | BioLegend | 836404 | B278794 | IB, 1/500 |
| Anti-SRY-related HMG-box protein (SOX) 10 | Santa Cruz Biotechnology | sc-365692 | F1621 | IB, 1/500 |
| Anti-Actin | MBL | M177-3 | 007 | IB, 1/80,000 |
| Anti-phospho-Akt1 (pSer473, which is essential for Akt1 activation) | Cell Signaling Technology | 9018S | 13 | IB, 1/500 |
| Anti-Akt1 | Cell Signaling Technology | 2938S | 2 | IB, 1/500 |
| Anti-angiotensin-converting enzyme (ACE) 2 | Santa Cruz Biotechnology | sc-390851 | F2520 | IB, 1/500 |
| Anti-pan-Ras | Santa Cruz Biotechnology | sc-166691 | H1220 | IB, 1/500 |
| Anti-green fluorescence protein (GFP) | Nacalai Tesque | 04404-84 | M7H8151 | immunoprecipitation, 1 mg for 1 mg proteins |
| Anti-GFP | MBL | M048-3 | 066 | IB, 1/1000 |
| Anti-DDDDK | MBL | M185-3L | 002 | IB, 1/10,000 |
| Anti-IgG (H+L chain) (Mouse) pAb-HRP | MBL | 330 | 365 | IB, 1/5000 |
| Anti-IgG (H+L chain) (Rabbit) pAb-HRP | MBL | 458 | 353 | IB, 1/5000 |
| Anti-PI 3-kinase p110α (PI3Ka) | Santa Cruz Biotechnology | sc-518070 | D2519 | IB, 1/250 |
| Anti-PI 3-kinase p110β (PI3Kb) | Santa Cruz Biotechnology | sc-376641 | H1320 | IB, 1/250 |
| Key chemicals | ||||
| guanosine triphosphate (GTP) | Merk | G8634-1MG | 056K1555 | 1 μM for immunoprecipitation |
| guanosine diphosphate (GDP) | Merk | 371545 | B62411 | 1 μM for immunoprecipitation |
| Glutathion-sepharose 4B | GE Healthcare | 17-0756-05 | 10058508 | 45 μL of 33% slurry (containing 30 μg of glutathion-S-transferase (GST)-Ras binding domain proteins) for 1 mg of total proteins in cell lysates |
| Protein G-sepharose 4FastFlow | GE Healthcare | 17-0618-01 | 10081061 | 45 μL of 33% slurry for 1 mg of total proteins in cell lysates |
| Lonafarnib as a Ras inhibitor | CAYMAN CHEMICAL | 11746 | 10081061 | 5 μM for cell treatment |
| MLN-4760 as an ACE2 inhibitor | MedChemExpress | HY-19414 | 305335-31-3 | 1 nM for cell treatment |
| Key reagents | ||||
| ScreenFect TM siRNA Transfection Reagent | FUJIFILM Wako Pure Chemical Corporation | 292-75013 | CAM0357 | |
| ScreenFect TM Dilution Buffer | FUJIFILM Wako Pure Chemical Corporation | 194-18181 | SKF5794 | |
| ImmunoStar Zeta | FUJIFILM Wako Pure Chemical Corporation | 295-72404 | LEP1844 | |
| Chemi-Lumi One Ultra | Nacalai Tesque | 11644-24 | L1G6389 | |
| Skim Milk Powder | FUJIFILM Wako Pure Chemical Corporation | 190-12865 | SKG4901 | |
| Western blotting (WB) Stripping Solution | Nacalai Tesque | 05364-55 | L5M5218 | |
| Gflex DNA Polymerase | TaKaRa Bio | R060A | AL80564A | |
| 2× Gflex PCR Buffer (Mg2+, dNTP plus) | TaKaRa Bio | R060A | AL80564A | |
| ISOGEN | Nippon Gene | 311-02501 | 75009K | |
| Sample Buffer Solution (2+Mercaptoethanol) (X4) | FUJIFILM Wako Pure Chemical Corporation | 191-13272 | WDP4995 | |
| Pre-stained Protein Markers (Broad Range) for SDS-PAGE | Nacalai Tesque | 02525 | L9M9989 | |
| 5×Prime Script Master Mix | TaKaRa Bio | RR036A | AIE0440A | |
| Recombinant protein | ||||
| Ras·GTP (active Ras)-binding domain of human c-Raf | Dr. Kenji Tago (Jichi Medical University, Tochigi, Japan) | N/A | N/A | |
| Cell line | ||||
| FBD-102b cells (mouse cells) | Dr. Yasuhiro Tomo-oka (Tokyo University of Science, Chiba, Japan) | N/A | N/A | |
| Plasmids and vectors | ||||
| pcDNA3.1-N-EGFP as the N-terminal GFP-tag expression vector | GenScript | not described | N/A | |
| pXR001: EF1a-CasRx-2A-EGFP | Addgene | 109049 | N/A | |
| pSINmU6 as the oligonucleotide transcription vector | TaKaRa Bio | not described | N/A | |
| ACE2 intracellular domain sequences (5′ to 3′) inserted into the plasmid (pcDNA3.1-N-EGFP) | ||||
| Sense-KpnI-oligonucleotide for human ACE2 intracellular domain-KpnI 5′-GGTACCGGGATCAGAGATCGGAAGAAGAAAAATAAAGCAAGAAGTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAATAATCCAGGATTCCAAAACACTGATGATGTTCAGACCTCCTTTTAGGGTACC-3′ Antisense-KpnI-oligonucleotide for human ACE2 intracellular domain-KpnI 5′-GGTACCCTAAAAGGAGGTCTGAACATCATCAGTGTTTTGGAATCCTGGATTATTTTCTCCTTTGCTAATATCGATGGAGGCATAAGGATTTTCTCCACTTCTTGCTTTATTTTTCTTCTTCCGATCTCTGATCCCGGTACC-3′ | This manuscript | N/A | N/A | |
| gRNA sequences (5′ to 3′) inserted into the plasmid (pSINmU6) | ||||
| Sense-BamHI-gLuciferase-ClaI gatccGCACCCGTGCAAAAATGCAGGGGTCTAAAACGGCGCCATTCTATCCTCTAGAGTTTTTTat Antisense-BamHI-gLuciferase-ClaI cgatAAAAAACTCTAGAGGATAGAATGGCGCCGTTTTAGACCCCTGCATTTTTGCACGGGTGCg | This manuscript | N/A | N/A | |
| Sense-BamHI-gACE2-93th-ClaI gatccGCACCCGTGCAAAAATGCAGGGGTCTAAAACGTCTTCAGCTTCCTGATTAAAGTTTTTTat Antisense-BamHI-gACE2-93th-ClaI cgatAAAAAACTTTAATCAGGAAGCTGAAGACGTTTTAGACCCCTGCATTTTTGCACGGGTGCg | This manuscript | N/A | N/A | |
| Sense-BamHI-gACE2-169th-ClaI gatccGCACCCGTGCAAAAATGCAGGGGTCTAAAACCACTCATCTTTTGGGCATTTTCTTTTTTat Antisense-BamHI-gACE2-169th-ClaI cgatAAAAAAGAAAATGCCCAAAAGATGAGTGGTTTTAGACCCCTGCATTTTTGCACGGGTGCg | This manuscript | N/A | N/A | |
| siRNA sequences (5′ to 3′) | ||||
| Sense chain for siLuciferase (siControl) GCCAUUCUAUCCUCUAGAG-dTdT Antisense chain for siLuciferase (siControl) CUCUAGAGGAUAGAAUGGC-dTdT | Yamauchi, J. et al. Exp. Cell Res. (2009) 315:2043-2052 | N/A | N/A | |
| Sense chain for siACE2-128th GUUCACUUGCUUCUUGGAA-dTdT Antisense chain for siACE2-128th UUCCAAGAAGCAAGUGAAC-dTdT | This manuscript | N/A | N/A | |
| Sense chain for siACE2-169th GAAAAUGCCCAAAAGAUGA-dTdT Antisense chain for siACE2-169th UCAUCUUUUGGGCAUUUUC-dTdT | This manuscript | N/A | N/A | |
| RT-PCR primers (5′ to 3′) | ||||
| Sense primer for Arf1 (internal control) ATGGGTGGCTTTTTCTCAAGTATTTTTTC Antisense primer for Arf1 (internal control) TCACTGTCTGCTTTTCAGGGTTTC | This manuscript | N/A | N/A | |
| Sense primer for ACE2 ATGTCCAGCTCCTCCTGGTCCTTC Antisense primer for ACE2 TCAGCATAGAGTTTGCCCAGAATCCTTGAGTCATATG | This manuscript | N/A | N/A |
Figure 1Knockdown of ACE2 by siRNA promotes oligodendroglial cell morphological differentiation. (A,B) FBD-102b cells were transfected with control or ACE2 siRNA and were allowed to be differentiated for 0 or 3 days. Differentiation efficiencies were divided into three categories and depicted in graphs (**, p < 0.01; n = 5 fields). Category 1 included cells with fewer than two primary branches; Category 2 included cells with fewer than three primary branches and without secondary branches; and Category 3 included cells with more than three primary branches and with secondary branches as well as with widespread membranes. Category 1 was considered to be the phenotypes before differentiation, whereas Category 3 was considered to be the differentiated phenotypes. Category 2 corresponded to these intermediate phenotypes. The number of branches in cells is also counted and shown (**, p < 0.01; n = 50 cells). (C,D) Cells at 3 days following the induction of differentiation were collected, lysed, and immunoblotted with an antibody against PLP1, CNPase, SOX10, or actin. Immunoreactive band intensities were also compared to be depicted in graphs (**, p < 0.01 and *, p < 0.05; n = 3 blots).
Figure 2Knockdown of ACE2 by gRNA promotes oligodendroglial cell morphological differentiation. (A,B) FBD-102b cells were transfected with the plasmids encoding ACE2 gRNA with CasRx or control plasmids and were allowed to be differentiated for 0 or 3 days. Differentiation efficiencies were divided into three categories and depicted in graphs (**, p < 0.01; n = 5 fields). The number of branches in cells is also counted and shown (**, p < 0.01; 50 cells). (C,D) Cells at 3 days following the induction of differentiation were collected, lysed, and immunoblotted with an antibody against PLP1, CNPase, SOX10, or actin. Band intensities were also compared to be depicted in graphs (**, p < 0.01 and *, p < 0.05; n = 3 blots).
Figure 3Knockdown of ACE2 promotes Akt1 phosphorylation whose site is essential for Akt1 activation. (A) The lysates of siRNA-knocked down FBD-102b cells were used for immunoblotting with an anti-phosphorylated (phospho) Akt1 or Akt1. These two different blots were performed from the same samples. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots). (B) The lysates of gRNA-knocked down cells were used for immunoblotting with an anti-phosphorylated (phospho) Akt1 or Akt1. These two different blots were performed from the same samples. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots).
Figure 4The intracellular domains of ACE2 interacts with Ras. (A) The lysates of FBD-102b cells were immunoprecipitated with an anti-ACE2 IgG or control IgG and then immunoblotted with an anti-Ras (pan-Ras) antibody. Total ACE2 and Ras proteins were also shown to confirm whether their expression levels are comparable. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots). (B) The lysates of cells transfected with the plasmid encoding GFP-tagged ACE2 intracellular domain (ICD) were immunoprecipitated with an anti-GFP antibody in the presence of 1 μM of GTP or GDP and then immunoblotted with an anti-Ras antibody. Total Ras and GFP-tagged proteins were also shown to confirm whether their expression levels are comparable. IgH and IgL indicate the probable heavy and light chains of immune globulins for immunoprecipitation experiments, respectively. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots).
Figure 5Knockdown of ACE2 promotes the GTP-bound form of Ras in affinity-precipitation assay. (A) The lysates of siRNA-knocked down FBD-102b cells were used for affinity-precipitation (AP) assay, monitoring activated GTP-bound Ras with Ras-binding domain (RBD). Total Ras proteins were also shown. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots). (B) The lysates of gRNA-knocked down cells were used for affinity-precipitation assay to monitor active GTP-bound Ras. Total Ras proteins were also shown. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots).
Figure 6Ras inhibition inhibits oligodendroglial cell morphological differentiation. (A,B) FBD-102b cells were treated with vehicle or Lanafamib (5 μM) and were allowed to be differentiated for 0 or 3 days. Differentiation efficiencies were divided into three categories and depicted in graphs (**, p < 0.01; n = 5 fields). The number of branches in cells is also counted and shown (**, p < 0.01; 50 cells). (C,D) Cells at 3 days following the induction of differentiation were collected, lysed, and immunoblotted with an antibody against PLP1, CNPase, SOX10, or actin. Immunoreactive band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots).
Figure 7Ras inhibition decreases Akt1 phosphorylation. The lysates of vehicle or Lanafamib-treated FBD-102b cells were used for immunoblotting with an anti-phosphorylated (phospho) Akt1 or Akt1. These two different blots were performed from the same samples. Band intensities were also compared to be depicted in graphs (**, p < 0.01; n = 3 blots).
Figure 8Schematic diagram of the relationship of the ACE2 and Ras signaling with morphological differentiation in FBD-102b cells. ACE2, acting through capturing Ras·GTP, inhibits oligodendroglial cell morphological differentiation (A), whereas ACE2 knockdown stimulates morphological differentiation through a possible pathway linking to Akt kinase (B).